


OUR SUPPORT FOR YOU

DEVELOPABILITY ASSESSMENT FOR ANTIBODIES



Late-stage failures in drug development often result from advancing molecules that are difficult to formulate or manufacture. Coriolis Pharma addresses this challenge by combining laboratory-based and *in silico* developability assessments to provide early insights into molecule characteristics and potential liabilities, optimize formulations, and mitigate risks. By streamlining decision-making processes and predicting stability and manufacturability issues early on, Coriolis helps developers reduce costs, accelerate timelines, and improve the likelihood of success from discovery to commercialization.


Accelerating Drug Development


Coriolis Pharma offers its clients a cutting-edge developability assessment platform, tailored for modern biologics drug development challenges.

This innovative service empowers biopharma companies with early-stage programs to make informed decisions quickly and efficiently.

Key Features

- Evaluates mAb candidates with minimal sample quantities (as low as single-digit milligrams)
- Combines unique analytical methods and *in silico* approaches
- Enables early decision-making, saving time and resources
- Reduces the risk of late-stage failures
- Different packages based on your development stage and goal





Our Approach

Choose from three developability packages with different focus:

- Candidate selection
- High concentration suitability
- Formulation sensitivity

Your Benefits

- You will unlock the full potential of your mAb candidates.
- You will make smarter decisions earlier in the development process and streamline your pipeline.
- You will accelerate your path to successful drug products for human application.
- You will start your journey with a service provider who does not leave you alone afterwards, but can continue to accompany your development until commercial success.

Further Modalities

You are not working on a mAb, but on a related molecule, a different kind of therapeutic protein or a peptide? Reach out to us and see whether the Coriolis developability platform can also be applied to your molecule.

Why Choose Coriolis?

- Full lifecycle support with the end goal in mind from preclinical to commercial under R&D and GMP
- Development of drug products designed for global launches, specifically meeting the requirements of the FDA, EMA and Japanese regulatory standards
- Client-focused collaboration with an independent service provider, offering dedicated attention to your specific project, molecule and development phase
- Bridging the gap between discovery phase and clinical development
- Scientifically robust approach for antibody candidate selection with the best chance of becoming a drug product
- Novel innovative methods published from Coriolis' team and scientific advisors to efficiently assess your antibody's biophysical properties
- Seamless development of your antibody drug product formulation for first clinical application ensuring a risk-appropriate approach
- Guidance and support until late-stage drug development through to market authorization
- Representatives in close proximity to you and your team with offices in the EU and USA

Headquarters

Fraunhoferstraße 18 b
82152 Martinsried
Germany
Phone: +49 89 41 77 60 – 0

U.S. Commercial Organization

455 E Eisenhower Pkwy
Suite 300, #1130
Ann Arbor, MI 48108
United States
Phone: +1 (256) 400-4491



www.coriolis-pharma.com/contact